Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including ...

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

Learn how to craft a resume that stands out by exploring 10 common resume mistakes and how to avoid them. Welcome to Career Coach, a column for job seekers and employees navigating the ins and outs of ...

Sales of Johnson & Johnson’s oncology drugs jumped nearly 19% in the third quarter, driven by cancer treatment Darzalex which ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on ...

Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...